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does not improve sur-
vival except for the
SRSF2 genotype.
• Treatment of AML with
3 cycles of intensive
therapy applied




Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in
acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been
lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients
age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and
intermediate-dose cytarabine (cycle 2) without orwith lenalidomide (15mg orally on days 1-21).
One final consolidation cycle of chemotherapy or autologous stem cell transplantation
(auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and
minimal residual disease (MRD)–adapted approach. Event-free survival (EFS; primary end
point) and other clinical end points were assessed. A second random assignment in patients
in complete response or in complete response with incomplete hematologic recovery after
cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21)
or observation. In all, 392 patients were randomly assigned to the control group, and 388
patients were randomly assigned to lenalidomide induction. At a median follow-up of 41
months, the study revealed no differences in outcome between the treatments (EFS, 44% 6
2% standard error and overall survival, 54% 6 2% at 4 years for both arms) although in an
exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML.
Submitted 18 November 2020; accepted 14 January 2021; published online 22
February 2021. DOI 10.1182/bloodadvances.2020003855.
To request data, please e-mail Bob Löwenberg at b.lowenberg@erasmusmc.nl.
The full-text version of this article contains a data supplement.
© 2021 by The American Society of Hematology
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In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss
Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen
but did not pursue an MRD-guided approach, these survival estimates compare markedly
more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the
risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect
on relapse probability in 88 patients randomly assigned for this part of the study.
Introduction
Treatment for acute myeloid leukemia (AML) in adults younger than
age 65 years with anthracycline-cytarabine–based combination
chemotherapy results in average complete remission (CR) rates of
70% to 85% and a long-term survival rate of about 40%. An inferior
outcome is seen in patients with unfavorable prognosis (as defined
by cytogenetic and molecular criteria) with a 5-year survival
probability of only 10% to 25%. In patients with comparatively
favorable subtypes of AML for whom treatment outcome is better,
the relapse rate may still be only 30% to 40%.1,2 Thus, in general,
there is a considerable need for more effective therapies in newly
diagnosed patients with AML. One approach aimed at improving
outcome focuses on combining drugs with distinct mechanisms of
action with other effective drugs as early in the treatment as
possible to tackle leukemia cells at multiple targets.
Lenalidomide belongs to the class of immunomodulatory drugs. It is
an orally available compound with antineoplastic, immunomodula-
tory, and antiangiogenic properties.3 Several studies, all of limited
size, have shown therapeutic activity of single-agent lenalidomide
in relapsed or refractory AML and previously untreated AML.4-6
Furthermore, antileukemic efficacy has been suggested in studies
that examined lenalidomide in combination with azacitidine7-11 or
chemotherapy.12,13 Previously reported data regarding the clinical
value of adding lenalidomide to chemotherapy at various levels of
dose intensity have been conflicting.12-15 But more definitive
studies exploring the therapeutic value of lenalidomide are lacking,
especially in the context of combination chemotherapy.
In the phase 3 study with mature follow-up reported here,
lenalidomide at a dose level of 15 mg/day in combination with
idarubicin-cytarabine (cycle 1) and intermediate-dose daunorubicin-
cytarabine (cycle 2) was evaluated in 780 newly diagnosed patients
(age 65 years or younger) with AML.
Patients and methods
Eligibility
Adults age 18 to 65 years with a diagnosis of AML or with refractory
anemia with excess blasts (RAEB) and a Revised International
Prognostic Scoring System score.4.5 16 or with acute leukemia of
ambiguous lineage according to World Health Organization 2008
criteria, an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of #2, and a written informed consent were eligible.
Eligibility and exclusion criteria are specified in detail in the
supplemental Data.
Study design and treatments
Eligible patients were randomly assigned in a 1:1 ratio to receive
remission induction therapy with or without lenalidomide (Figure 1).
Random assignment was performed by using aminimization procedure
to ensure balance in the number of patients enrolled to each
treatment arm overall, within each registration center and
diagnostic subgroup (AML, RAEB, or leukemia with ambiguous
lineage). Cycle 1 included idarubicin at 12 mg/m2 (3-hour infusion
on days 1, 2, and 3) and cytarabine at a dose of 200 mg/m2 (per
continuous infusion on days 1-7) with or without lenalidomide.
Cycle 2 contained daunorubicin 60 mg/m2 per 1-hour infusion
on days 1, 3, and 5 plus cytarabine 1000 mg/m2 given intravenously
for 3 hours twice per day on days 1 to 6 with or without the
addition of lenalidomide. The study began with a dose-selection
run-in phase with an initial dose of lenalidomide of 20 mg/day
on days 1 to 21 in cycles 1 and 2 (details are provided in the
supplemental Data) and then continued with lenalidomide at
15 mg/day as an open-label phase 3 trial (part A of the trial),
which is reported here.
Patients in CR or CR with incomplete hematologic recovery
(CRi) after cycle 2 received consolidation with 1 final additional
cycle of intensive chemotherapy with mitoxantrone-etoposide
(cycle 3) or autologous stem cell transplantation (auto-SCT)
after conditioning with busulfan-cyclophosphamide or total body
irradiation-cyclophosphamide,2 or allogeneic SCT (allo-SCT),
depending on their baseline prognostic risk status and minimal
residual disease (MRD) status after the first 2 induction cycles as
described (details are provided in the supplemental Data).
After consolidation treatment with cycle 3 or auto-SCT and
meeting predefined eligibility criteria for maintenance treatment
(supplemental Data), patients were eligible for a second random
assignment (part B of the trial) to receive either 6 cycles of
lenalidomide maintenance (at a fixed dose of 10 mg/day on days
1-21 followed by 14 days of rest) or observation (Figure 1),
regardless of whether they had been assigned to the control or
lenalidomide induction treatment at the first random assignment.
Patients who received an allo-SCT as consolidation therapy
were not eligible for the second random assignment. Random-
ization minimization factors in part B of the trial were registration
center, diagnostic subgroup, treatment arm of the induction
randomization, and type of consolidation treatment.
The study was approved by the ethics committees of the
participating institutions and was conducted in accordance
with the Declaration of Helsinki. All patients gave their written
informed consent.
Risk classification and clinical characteristics
On the basis of the European LeukemiaNet (ELN) risk classifica-
tion,1 patients were classified into prognostic categories. Patients
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with previous myelodysplastic syndrome (MDS) or other ante-
cedent hematologic disease (including myeloproliferative dis-
eases) diagnosed 3 months or more before the AML/RAEB
diagnosis were classified as secondary AML (sAML). Patients
with previous chemotherapy or radiotherapy (and no sAML) were
classified as therapy-related AML (tAML). Clinical and hemato-
logic parameters, including ECOG performance status, extra-
medullary disease, and white blood cell count (WBC) were
registered at diagnosis.
Criteria for response and end points
Criteria for CR, CRi, and relapse were as described.2 The
primary end point for part A of the trial, which evaluated the
added value of lenalidomide during induction, was event-free
survival (EFS), which refers to the interval from induction
randomization to the date of failure to achieve CR/CRi within 2
induction cycles, death without relapse after achieving CR/CRi, or
relapse after achieving CR/CRi, whichever occurred first. Second-
ary efficacy end points for part A of the trial included overall survival
(OS), relapse-free survival (RFS), rate of hematologic response
during and after induction, and MRD negativity rate after induction
cycle 2.
The primary end point for part B of the trial, which evaluated the
value of maintenance treatment with lenalidomide, was cumulative
incidence of relapse (CIR) defined as the time from the date of
second random assignment until the date of relapse. Secondary
end points for part B are cumulative incidence of death, RFS,
and OS, all measured from the second random assignment.
Safety was evaluated by observed adverse events (AEs), including
pulmonary embolism, thromboembolic events, second primary
malignancy, (early) mortality, and the need for transfusions,
hospitalizations, and time to hematologic recovery after each
chemotherapy cycle.
Molecular analysis and MRD assessment
Targeted sequencing and other methods used for the molecu-
lar assessment of common AML-associated gene mutations and
high EVI1 messenger RNA expression on bone marrow or blood
specimens at diagnosis were performed as previously reported2
with minor changes (specified in supplemental Data), and the
molecular biomarkers are listed in Table 1. MRD was assessed after
cycle 2 in patients in morphologic CR/CRi with multiparameter flow
cytometry (MFC) and reverse transcriptase polymerase chain
reaction (RT-PCR) for mutated NPM1 as described.17-19
For the purpose of the analysis, MRD negativity is defined as the
absence of mutant NPM1 by quantitative RT-PCR (,1024) and
in NPM1-wild-type patients as negative by MFC (below 0.1%). If
RT-PCR assessment for mutated NPM1 AML was not available,
the MFC results became the leading results.
Statistical analysis
The trial was powered for EFS, the primary end point for part A of
the trial. Assuming the target sample size of 800 patients was to
be accrued in 3 years with an additional follow-up of 1 year after
the end of enrollment, we estimated that 441 EFS events would
be observed by the time of the analysis, and the trial would have
82% power, at a 2-sided significance level of 5% by a log-rank
test, to detect a hazard ratio (HR) for EFS of 0.76 (corresponding
to an increase in the 3-year EFS rate from 38% in the control arm
to 48% in the lenalidomide arm). But when after 2.5 years after
the last patient enrollment the target number of events had not
yet been reached (427 events reported by February 2020), the
Data and Safety Monitoring Board (DSMB) recommended not
waiting for the additional events and performing the final trial
analysis as soon as all relevant clinical data were clean and as
up-to-date as possible.
Ara-C 200mg/m2 d1-7c.i.
Idarubicin 12 mg/m2 3-hr d1-3
Ara-C 1000mg/m2 3-hr bid d1-6
Daunorubicin 60 mg/m2 iv d1, 3, 5
Randomization for induction
with or without lenalidomide
Randomization for yes/no
maintenance
Remission induction cycle I
Remission induction cycle II
Consolidation therapies for




Study Scheme Phase III lenalidomide study in newly
diagnosed AML/RAEB, 18-65 yrs
Lenalidomide
6 cycles
10 mg days 1-21
Ara-C 200mg/m2 d1-7c.i.
Idarubicin 12 mg/m2 3-hr d1-3
Lenalidomide days days 1-21
Ara-C 1000mg/m2 3-hr bid d1-6
Daunorubicin 60 mg/m2 iv d1, 3, 5
Lenalidomide 15 mg days 1-21
Figure 1. Study schema. Ara-C, cytarabine; bid, twice per day; c.i., continuous infusion; d, day; hr, hour; iv, intravenous; R, random assignment.
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In all, 253 of 800 enrolled patients were expected to proceed to part
B of the trial. Ultimately, however, only 88 patients were randomly
assigned for maintenance with lenalidomide vs observation, which
means that the analyses of this part of the trial are greatly
underpowered and hence the significance of the latter results is
limited.
All analyses were performed according to the intention-to-treat
principle, irrespective of protocol compliance, but 20 of 800
patients who seemed ineligible after registration were excluded
(7 in the control arm and 13 in lenalidomide arm; reasons for
ineligibility are provided in the supplemental Data).
Cox regression analysis was used to analyze the effect of
treatment on EFS, OS, and RFS with and without adjustment
for other covariates, and the response rate variables were
analyzed with the use of logistic regression. Because only 2
patients died between the date of second random assignment
and the time of the analysis, cumulative incidence of death from
Table 1. Patient characteristics at baseline according to random










Total 392 (100) 388 (100)
Male sex 210 (54) 233 (60)
Age, y
Median (range) 53 (18-65) 54 (18-65)
#45 110 (28) 99 (26)
46-60 194 (49) 195 (50)
.60 88 (22) 94 (24)
WHO/ECOG performance status
0 239 (61) 264 (66)
1 138 (35) 113 (29)
2 15 (4) 11 (3)
Diagnostic subgroup
AML 356 (91) 351 (90)
High-risk RAEB 33 (8) 35 (9)
Leukemia with ambiguous lineage 3 (1) 2 (1)
AML type
De novo 358 (91) 351 (90)
sAML 19 (5) 24 (6)
tAML 15 (4) 13 (3)
WBC, 3 109/L
Median (range) 8.0 (0-265) 6.7 (0.4-297)
#20 259 (66) 257 (66)
20-100 109 (28) 103 (27)
.100 23 (6) 27 (7)
Unknown 1 (0) 1 (0)
Median blasts in bone marrow, % 52 52
Cytogenetics*
t(8;21) 11 (3) 22 (6)
inv(16) or t(16;16) 23 (6) 26 (7)
CN-X-Y 211 (54) 199 (51)
CA rest 97 (25) 95 (24)
Monosomal karyotype 39 (10) 34 (9)
Unknown 11 (3) 12 (3)
Gene mutations†
NPM1-mut 744 129 (33) 115 (30)
FLT3-ITD-mut 742 85 (22) 69 (18)
FLT3-TKD835-mut 742 34 (9) 33 (9)
NPM1-mut FLT3-ITD-negative 741 69 (18) 77 (20)
NPM1-mut FLT3-ITD-mut 59 (15) 38 (10)
NPM1-wt FLT3-ITD-negative 217 (55) 224 (58)
NPM1-wt FLT3-ITD-mut 26 (7) 31 (8)
DNMT3A-mut 739 108 (28) 105 (27)
IDH1-mut 739 35 (9) 34 (9)
IDH2-mut 739 45 (11) 45 (12)
TET2-mut 739 54 (14) 41 (11)











RUNX1-mut 742 41 (10) 49 (13)
ASXL1-mut 742 39 (10) 31 (8)
TP53-mut 742 28 (7) 29 (7)
SF3B1-mut or SRSF2-mut‡ 739 46 (12) 43 (11)
SRSF2-mut‡ 739 30 (8) 28 (7)
PTPN11-mut 739 44 (11) 33 (9)
KRAS-mut 739 23 (6) 18 (5)
NRAS-mut 739 60 (15) 69 (18)
JAK2-mut 739 3 (1) 4 (1)
BCOR-mut or BCOR1-mut 739 29 (7) 25 (6)
EVI1 overexpression 594 21 (5) 28 (7)
Prognostic risk according to 2017 ELN
criteria§
Favorable 134 (34) 150 (39)
Intermediate 127 (32) 94 (24)
Adverse 119 (30) 139 (36)
Unknown 12 (3) 5 (1)
All data are n (%) unless otherwise indicated. RAEB is defined as having a Revised
International Prognostic Scoring System score .4.5.16
CA, abnormal cytogenetics; CN, normal cytogenetics; ECOG, Eastern Cooperative
Oncology Group; mut, mutation; sAML, secondary AML (after myelodysplastic syndrome
and antecedent hematologic disease); tAML, therapy-related AML (in case of previous
chemotherapy or radiotherapy) (for details see “Patients and methods”); WHO, World
Health Organization; wt, wild-type.
*AML with core binding factor abnormalities: t(8;21)(q22;q22), inv(16)(p13.1;q22), or
t(16;16)(p13.1;q22); monosomal karyotype defined as described in Breems et al.20
†Gene mutations include ASXL1, additional sex combs–like 1; CEPBA, CCAAT/
enhancer-binding protein a; DNMT3A, DNA methyltransferase 3 a; EVI1, ecotropic virus
integration 1; FLT3, fms-like tyrosine kinase-3; FLT3-ITD-negative, FLT3 without internal
tandem duplications (ITDs); FLT3-TKD835, FLT3-tyrosine kinase domain 835, FLT3 gene
with point mutation at position D835; IDH1/IDH2, isocitrate dehydrogenase 1 and 2;
NPM1, nuclephosmin-1; PTPN11, protein tyrosine phosphatase nonreceptor type 11;
RUNX1, runt-related transcription factor 1; SF3B1, splicing factor 3B subunit; SRSF2,
serine/arginine-rich splicing factor 2; TET2, Tet methylcytosine dioxygenase 2.
‡We considered the frequencies of SRSF2 alone and SRSF2 and SF3B1 in
combination.
§The ELN prognostic risk categories as described in Döhner et al.1
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the second random assignment was not evaluated, and the CIR
from the second random assignment was analyzed using Cox
regression. The between-arm difference of the time to recovery
after each chemotherapy cycle was tested by means of Fine
and Gray regression.
All reported P values are 2-sided, and values of P , .05 were
considered statistically significant. No corrections were made for
multiple testing. Statistical analyses were performed with STATA
Statistical Software, Release 15.1 (STATA, College Station, TX).
Details of the statistical analyses are provided in the supplemental
Data. Data for this analysis were locked as of 19 May 2020. At
the time of the analysis, no patients were receiving the trial
treatment and no patients were awaiting random assignment to
maintenance therapy. The trial treatment was discontinued in
the last patient in June 2019.
Results
Patients
Between 2 February 2015, and 9 August 2017, 800 patients, including
68 with MDS-RAEB, were randomly assigned to induction
treatment with or without lenalidomide; 20 patients turned out
to be ineligible (see the supplemental Data for details), leaving
780 eligible and evaluable patients for the final analysis. In all,
392 patients were assigned to the standard induction regimen
and 388 were assigned to the lenalidomide induction regimen
(supplemental Figure 1A-B). Median follow-up time for patients
still alive at the date of last contact (n 5 436) was 41 months.
Table 1 presents the demographic and molecular characteristics
of the patients. Median age was 54 years with 23% of patients
between age 61 and 66 years. Both treatment groups were
comparable regarding clinical, hematologic, cytogenetic, and
molecular features.
Treatment, response, and outcome
Of 780 patients, 777 (99.6%) received induction cycle 1
starting at a median of 1 day after study registration. At a
median of 37 days after registration, 666 (85%) of 780 patients
began treatment with induction cycle 2 (Table 2; supplemental
Figure 1A-B). The actual delivery of total doses of anthracy-
cline, cytarabine, and lenalidomide relative to the intended
protocol dose levels are given in the supplemental Data. The
percentage of patients attaining CR or CRi after induction on
Table 2. Treatment and outcomes comparison between control and lenalidomide remission induction
Control induction therapy Lenalidomide induction therapy
Logistic/Cox regression*
OR/HR 95% CI P
Total no. of patients 392 (100) 388 (100)
Treatment
Remission induction
Cycle 1 391 (100) 386 (99)
Cycle 2 340 (87) 326 (84)
Consolidation therapy after CR/CRi 279 (71) 254 (65)
Cycle 3 25 (6) 34 (9)
Auto-SCT 94 (24) 76 (20)
Allo-SCT 160 (41) 144 (37)
Outcomes
CR/CRi after induction 340 (87) 319 (82) 0.71 0.48-1.05 .08
Early CR/CRi (attained before remission induction cycle 2) 276 (70) 254 (65)
Early death
Death within 30 days 11 (3) 18 (5)
Death within 60 days 20 (5) 26 (7)
At 4 years (% 6 SE):
EFS† 44 6 3 44 6 3 0.99 0.82-1.20 .96
OS† 54 6 3 54 6 3 0.98 0.79-1.21 .83
RFS†
RFS 49 6 3 51 6 3 0.95 0.77-1.18 .66
Relapse 39 6 3 36 6 3
Death 12 6 2 13 6 2
MRD negativity after cycle 2‡ 167 (78) 161 (77) 0.92 0.59-1.46 .73
All data are n (%) unless otherwise indicated. OR is estimated for CR/CRi after induction and for MRD negativity rate after cycle 2. HR applies to EFS, OS, and RFS.
*Logistic/Cox regression included induction treatment arm and diagnostic subgroup (AML or RAEB) as covariates.
†Percentages are actuarial 4-year probabilities.
‡MRD negativity rate is evaluated relative to 424 patients with evaluable MRD after induction cycle 2 (214 in the control arm and 210 in the lenalidomide arm).
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protocol was 87% for the control group and 82% for the
lenalidomide treatment group, with no statistically significant
difference (odds ratio [OR], 0.71; 95% confidence interval
[CI], 0.48-1.05; P 5 .08) (Table 2). Subsequently, 59 (8%) of
780 patients received chemotherapy cycle 3, 170 (22%)
underwent auto-SCT, and 304 (39%) proceeded to allo-SCT.
The percentages of complete responders (CR/CRi) who
received cycle 3, auto-SCT, or allo-SCT were 9%, 26%, and
46%, respectively.
Table 2 summarizes the values for the distinct clinical end
points split by treatment group. For the analysis of EFS, 430
events were observed. The median EFS was 24 months for the
control group and 21 months for the lenalidomide treatment
group, which corresponds with respective EFS rates at 4 years
of 44% 6 3% (standard error [SE]) and 44% 6 3%, which
implies no advantage for lenalidomide (HR, 0.99; 95% CI, 0.82-
1.20; P 5 .96) (Table 2; Figure 2). The latter conclusion
remains unchanged after adjustment for known prognostic
factors at diagnosis (WBC [log-transformed], age, 2017 ELN
risk group, AML type) (Table 3). When we accounted for allo-
SCT and for consolidation treatment in general, no difference
in EFS estimates between the control and lenalidomide
treatment groups became apparent either. Further, no differ-
ential effect of treatment on competing risks of EFS was
observed.
Median OS was 56 months for the control treatment, and it was
not yet reached in the lenalidomide group. For the combined treat-
ment groups, the 4-year OS was estimated at 54%6 2% (SE) with
no difference between the 2 arms (HR, 0.98; 95% CI, 0.79-1.21;
P 5 .83) (Figure 2). Further adjustment for allo-SCT and for
consolidation treatment did not alter the results.
In those with CR or CRi, the 4-year RFS was 50% 6 2% with
no difference between the 2 arms (HR, 0.95; 95% CI, 0.77-1.18;
P 5 .66). Nor was a between-arm difference observed for the
competing risks of RFS (ie, relapse and nonrelapse mortality)
(Table 2).
Prognostic factors and subgroup analysis
In an exploratory analysis, the possible differential effect of
lenalidomide treatment on EFS and OS was evaluated in a variety
of subgroups distinguished by prognostic factors for treatment
outcome (patient age at registration, AML type (de novo AML,
sAML, tAML), disease type (AML, RAEB), WBC at diagnosis, and
2017 ELN risk group; EFS results are provided in supplemental
Figure 2) and also according to molecular genotypes. No convinc-
ing indications were found that selected prognostic subgroups
benefit from addition of lenalidomide (compared with the control
treatment), except for a statistically significant survival advantage
for treatment with lenalidomide in 58 patients with SRSF2-
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Figure 2. EFS and OS following lenalidomide remission induction therapy vs control induction treatment. EFS (A) and OS (B) for patients receiving
remission induction therapy (control group vs lenalidomide [Lena] therapy group). Patients were randomly assigned for their first and second induction cycles
of combination chemotherapy without additional lenalidomide (control treatment) or with lenalidomide at 15 mg on days 1 to 21 of both cycles. F, failure (or
event).
Table 3. Multivariable Cox regression analysis for EFS
Variable HR 6 SE 95% CI P
Lenalidomide treatment 0.96 6 0.09 0.79-1.17 .70
Age 1.00 6 0.00 1.00-1.01 .30
WBC 1.07 6 0.04 1.01-1.15 .03
2017 ELN risk group ,.001
Favorable 0.55 6 0.07 0.42-0.71 ,.001
Adverse 1.48 6 0.17 1.18-1.87 ,.001
Unknown 0.57 6 0.21 0.27-1.16 .10
AML type .04
sAML 1.61 6 0.30 1.11-2.33 .01
tAML 1.09 6 0.28 0.66-1.82 .73
The following covariates were considered for this analysis: patient age, WBC 3 109/L at
diagnosis (log transformation), 2017 ELN risk category1 (values expressed relative to
intermediate-risk group), sAML and tAML (relative to de novo AML).
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0.23-0.96; P 5 .04; supplemental Figure 2). This difference is
explained by a lower relapse rate in the lenalidomide treatment
group (67% vs 42% RFS at 4 years; HR, 0.39; 95%CI, 0.17-0.93;
P 5 .03). The advantage of lenalidomide treatment in the SRSF2-
mutated subset was also apparent regarding OS (68% vs 43% at
4 years; HR, 0.42; 95% CI, 0.19-0.94; P5 .03). Remarkably, in the
current risk-adjusted treatment study without the use of an FLT3
inhibitor, FLT3-internal tandem duplication (FLT-ITD) does not express
any prognostic value or for either high or low allelic ratios (EFS: 43%
FLT3-ITD1 vs 45% FLT3-ITD– at 4 years; HR, 1.12; 95% CI, 0.88-
1.42;P5 .35; OS: 59%FLT3-ITD1 vs 53%FLT3-ITD– at 4 years; HR,
0.90; 95% CI, 0.68-1.19; P 5 .47; supplemental Figure 3).
Assessment of MRD in CR/CRi after cycle 2
MRD status after induction cycle 2 was evaluated centrally
according to protocol with NPM1 qRT-PCR and MFC in 424 (64%)
of 666 patients who had received cycle 2 and continued in
CR/CRi. Among these patients, the overall MRD negativity rate
after induction cycle 2 was 77% with no difference between the
comparative treatment arms (OR, 0.92; 95% CI, 0.59-1.46; P 5 .73)
(Table 2).
MRD positivity after induction cycle 2 correlated with a
significant negative impact on RFS (43% vs 57% at 4 years;
HR, 1.75; 95% CI, 1.27-2.40; P 5 .001) and OS (51% vs 66%
at 4 years; HR, 1.98; 95% CI, 1.39-2.81; P , .001); however,
there was no apparent difference in outcome between the
control and lenalidomide treatment groups or in MRD-positive
patients or in MRD-negative patients (Figure 3). MRD in-
formation is generally considered most useful for guiding
treatment choice in intermediate-risk AML. It seems that when
choosing MRD-guided treatment, the prognostic significance
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Figure 3. Relapse-free survival of complete responders after remission induction therapy according to MRD-negative/positive status. RFS according to
attainment of MRD negativity for all patients (A), in the subgroup of patients with persistent positive MRD (B), and in those attaining a status of MRD negativity according to
remission induction therapy (control group vs lenalidomide therapy group) (C). The unfavorable effect of MRD positivity is evident, but there is no apparent effect of
lenalidomide treatment on outcome in patients attaining a status of MRD negativity or in patients with persistent MRD.
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Furthermore, especially among the consolidated intermediate-
risk patients with negative MRD, 31% proceeded to auto-SCT
and 55% proceeded to allo-SCT, whereas in those with positive
MRD, only 8% proceeded to auto-SCT and 88% proceeded to
allo-SCT. The data suggest that, in MRD-negative intermediate-
risk patients, auto-SCT furnishes an effective alternative to allo-
SCT in terms of OS (OS in the MRD-negative subgroup: 76%
auto-SCT vs 68% allo-SCT at 4 years; HR, 0.71; 95% CI, 0.27-
1.86; P 5 .49; RFS in the MRD-negative group: 52% auto-SCT
vs 62% allo-SCT at 4 years; HR, 1.45; 95% CI, 0.69-3.07; P 5
.33; for survival curves, see supplemental Figure 4). Of note,
analyses showed similar relationships for patients with
favorable-risk disease (supplemental Figure 5). Obviously,
these conclusions should be interpreted with some caution
because of low numbers of patients and the nonrandomized
comparison of the consolidation options.
Safety and tolerability
The 2 treatment arms were compared with respect to AEs,
time of neutrophil and platelet recovery, platelet transfusion
requirements, and number of nights spent in the hospital
(supplemental Table 1). The incidence and severities of AEs
were comparable between the arms during induction and
maintenance phase with no apparent differences in the frequen-
cies of AEs of special interest (eg, pulmonary embolism and
thrombosis with a frequency of 5% after cycle 1 and 6% after
induction cycle 2). The frequencies of patients presenting with
second primary malignancies registered during study follow-up
was 4% and did not differ between the treatment arms.
Time to neutrophil and platelet recovery and platelet transfusion
requirements after induction cycle 1 did not differ, but after cycle
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Figure 4. Prognostic value of MRD status after remission induction in distinct AML risk groups in context of MRD-guided consolidation treatment choice.
RFS by MRD status after induction cycle 2 in favorable risk (A), intermediate risk (B), and adverse risk (C) 2017 ELN risk classification groups. The prognostic significance of
MRD positivity is lost in intermediate-risk AML in the context of MRD-guided treatment choice.
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progressively delayed in patients assigned to lenalidomide
treatment. By comparison, the median number of days to
neutrophil and platelet recovery was prolonged by an additional
2 to 4 days after cycle 2, and the median recovery intervals for
neutrophils and platelets after chemotherapy in cycle 3 were
delayed by an extra 11 and 24 days, respectively (supplemental
Table 1). Patients in the lenalidomide treatment group remained
dependent on platelet transfusions during prolonged intervals
after cycle 2 and cycle 3. Cycle 3 patients who received
lenalidomide during induction spent more nights in the hospital
(supplemental Table 1). Early mortality rates (at 30 and 60 days)
were 4% and 6%, respectively, with no differences between the
treatment groups.
Randomization for maintenance with lenalidomide
In part B of the trial, 45 patients were assigned to lenalidomide
maintenance and 43 patients were assigned to observation. These
patients had a median age of 47 years and included 65%males and
3 patients with RAEB, but there were no notable differences in
clinical or hematologic characteristics between the groups (data
not shown). Detailed actual dose delivery of study drug is described
in the supplemental Data. The percentage of patients who
experienced relapse (primary end point for this part of the trial)
was 24% in the lenalidomide maintenance group and 28% in the
observation group. The data revealed no differences between
maintenance and observation regarding CIR with an HR of 0.81








































































42 40 18 2
Months
A B
Figure 5. Relapse probability and OS of complete responders following maintenance treatment with lenalidomide or observation. CIR (A) and OS (B) in
patients in CR/CRi randomly assigned between lenalidomide maintenance treatment and observation.
Table 4. Patient outcome according to random assignment for lenalidomide maintenance or observation
Observation Lenalidomide maintenance
Cox regression*
HR 95% CI P
Total 43 (100) 45 (100)
Outcomes
Relapse after second randomization 12 (28) 11 (24)
Death after second randomization 8 (19) 4 (9)
Relapse-free mortality after second randomization 2 (5) —
At 3 years (% 6 SE):
CIR† 34 6 10 28 6 8 0.81 0.36-1.85 .62
RFS† 67 6 7 75 6 6 0.70 0.32-1.55 .38
OS† 84 6 6 91 6 4 0.51 0.15-1.72 .28
MRD positive
Before second randomization 2 (5) 4 (9)
After second randomization 2 (5) 1 (2)
Data are n (%) unless otherwise stated.
*Cox regression included maintenance treatment arm, induction treatment arm, and type of consolidation treatment as covariates.
†Percentages are actuarial 3-year probabilities.
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(HR for OS, 0.51; 95% CI, 0.15-1.72; P 5 .28), implying that
there is no suggestion of a benefit for lenalidomide treatment
after consolidation (Table 4).
MRD status was also assessed in a small number of patients at
6 months after the second random assignment and compared with
the MRD status immediately before the second random assignment.
The status of MRD negativity and positivity did not differ according
to the randomization (Table 4).
Discussion
Preclinical and early clinical studies with single-agent lenalido-
mide and lenalidomide plus hypomethylating agent or chemo-
therapy drug combinations provided contradictory data about
the potential therapeutic value of lenalidomide in the treatment
of AML.7-15 This article reports the first large phase 3 study with
mature follow-up in a head-to-head comparison on the use of
lenalidomide as an adjunct integrated into intensive remission
chemotherapy in newly diagnosed patients with AML younger
than age 66 years. The results of the study fail to furnish
indications for a positive therapeutic effect regarding various
clinical parameters, including response rates, achievement of
MRD negativity, EFS, and other survival end points. Although
current established first-line treatments in AML need to be
improved in terms of efficacy, it appears that the addition of
lenalidomide does not satify this need. One question is whether
we have used an optimal dosing schedule. In some other
studies, lenalidomide was given at higher daily dose levels (even
up to 50 mg) and/or over prolonged intervals for more days, but
in several instances the tolerability caused problems.11,14 In
our study, the run-in randomized study in 127 patients demon-
strated excess toxicity (infections, hematologic effects) for
a dose of 20 mg so that based on the recommendations of the
independent DSMB, a final dose of 15 mg was selected for the
phase 3 study. The safety of lenalidomide at the selected dose
was manageable (eg, in terms of AEs and early mortality), but the
addition of lenalidomide generated cumulative hematologic
toxicities that became apparent from cycle 2 onward as evidenced
by the delayed neutrophil and platelet recovery times, the increase
in transfusion requirements, and the increase in hospitalization
days. A more plausible explanation for the failure of lenalidomide
therapeutic efficacy in this study is that lenalidomide is at best
a moderately active drug in AML that adds little value to
an intensive treatment regimen, at least in the general AML
population. This is consistent with previous experiences of failure
on multiple occasions of adding cytotoxic drugs to 713–like
treatment regimens. In light of the considerable genetic hetero-
geneity of AML, it is an unrealistic logistic and methodologic
challenge to test the potential value of a specific drug in individual
sybtypes across the diverse disease genotypes with sufficient
power. A general 713–based treatment approach evidently is
far from ideal for identifying potential benefits of a new drug
for a particular subtype; in this study, in an exploratory and
hypothesis-generating analysis, lenalidomide showed indica-
tions for survival and relapse benefits in SRSF2-mutant AML.
Whether these positive effects are true would require
further study.
Our study lacked statistical power regarding a robust evaluation
of lenalidomide for maintenance, although most of the randomly
assigned patients were able to receive at least 5 cycles of
lenalidomide. Only 88 (42%) of 212 patients who had received
cycle 3 or auto-SCT and had remained in CR/CRi entered this
part of the study. The reason for the relatively small numbers
of patients enrolled relates to the strict inclusion criteria that
excluded many patients for reasons of intercurrent relapse,
refusal of treatment, and not fulfilling the condition of absolute
neutrophil count $1.5 3 109/L and platelet count $75 3 109/L
(supplemental Figure 1A-B).
In a general sense, it is notable that this study, with an 84% CR/
CRi rate after no more than 2 induction cycles and only 1 risk-
adapted consolidation treatment (cycle 3, auto-SCT, or allo-
SCT), showed favorable EFS (44% at 4 years) and OS (54% at
4 years) and median OS estimates of 61 months compared
with historical studies.2 The EFS and OS results, for instance,
are distinctly better than those of our most recent previous
study of similar size and with a similar median age of 55 years
(EFS 36% and OS 43% at 4 years) which, being at variance
with this study, had not applied MRD guidance for post-
remission treatment assignment and had fewer patients
allocated to auto-SCT (8% vs 22% in this study).2 MRD is
especially clinically relevant for informing treatment choice in
intermediate-risk AML. Thus, the similar treatment outcomes
of patients in the intermediate prognostic AML spectrum with
positive MRD and negative MRD (of whom many were
consolidated with auto-SCT with avoidance of allo-SCT) is
reassuring about the value of MRD-adapted treatment choice
(RFS: 50% MRD-positive vs 52% MRD-negative at 4 years;
HR, 1.18; 95% CI, 0.65-2.14; P 5 .59; OS: 64% MRD-positive
vs 69% MRD-negative at 4 years; HR, 1.31; 95% CI, 0.64-2.69;
P 5 .46).
Finally, this large study allowed for additional clinically relevant
observations. First, detailed centralized molecular diagnostics
and MRD monitoring in an international multicenter setting
confirmed the prognostic value of MRD status in CR/CRi for
survival (RFS and OS), although it seems that in this case, the
risk-adjusted treatment may have reduced its quantitative
impact. Second, the era of studies in molecular/biologic
nonstratified AML has ended. Our study is likely one of the
last to be conducted in FLT3-mutated AML that applied
713–based remission induction therapy without an FLT3
inhibitor. It is informative to note that in this risk-adapted study,
there was absolutely no indication of a negative prognostic
impact of FLT3-ITD on outcome for either high or low
mutational FLT3-ITD burden.
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